Market PotentialAnalyst believes AVERSA Fentanyl can be the first abuse-deterrent transdermal fentanyl patch, which could lead to taking market share from the current generic transdermal patches.
PartnershipNutriband has a partnership with Kindeva Drug Delivery, formerly part of 3M, to add the AVERSA technology to Kindeva’s transdermal fentanyl patch.
Product DevelopmentThe AVERSA Fentanyl patch could prevent abuse and accidental misuse of fentanyl transdermal patches, potentially allowing for decreased restrictions and improved access for patients with severe chronic pain.